26 May 2026US SMID-Cap BiopharmaceuticalsSummit Therapeutics Inc.RatingUnderperformPrice TargetSMMT7.70 USDJeffrey Walch+1 917 344 8613jeffrey.walch@bernsteinsg.comYi Zhao+1 917 344 8324yi.zhao@bernsteinsg.comReported EPSF25AF26EF27ESMMT (USD)(1.44)(0.96)(0.89)FinancialsF25AF26EF27ECAGREBITDA (M)(1,094)(768.02)(760.22)--Revenues (M)0211Valuation MetricsF25AF26EF27EReported P/E (x)(12.1)(18.2)(19.7)EV/Sales (x)N/MN/MSource: Bloomberg, Bernstein estimates and analysis.Summit: Counting down to the HARMONI6 ASCO plenary, ourbase case is non-statistically significant OS trendInvestment ImplicationsWe maintain an Underperform rating on SMMT. We recommend investors exit positions or,if possible, initiate short positions. In our opinion the long-term outlook for the company isnot on solid footing. Both SMMT and BioNTech have aggressively jumped into the misguided(based on our analysis) PD-L/VEGF bispecific experiment. This strategy could prove evenmore costly for SMMT than BioNTech because ivonescimab is their only drug in development.Unlike BNTX, SMMT has no on-market drugs, revenue or additional late-stage assets.We expect the key end-points for all three of SMMT’s ongoing Ph3 trials to read-out non-statistically significant: overall survival for HARMONi-3/-7 in NSCLC and PFS for HARMONi-GI3 in MSS colorectal cancer. There is an expansive history of failed registrational trialsinvestigating the combination of anti-PD-1+ anti-VEGF across tumor types. We discount thenarrative that “this time it’s different” for anti-PD-1+VEGF as lacking in supportive clinicaldata. Instead, we initiate with an Underperform rating because the science and clinical datatells us that history will repeat itself: encouraging PFS HR that degrades to negative OS and afailed clinical trial.We rate SMMT Underperform with PT $7.70 (-56%) based on our DCF valuation.Close Date 21 May 2026SMMT Close Price (USD) 17.47Price Target (USD) 7.70Upside/(Downside) (56)%52-Week Range 30.98/13.83SPX7,473.47FYE DecDiv Yield NAMarket Cap (USD) (M) 13,040EV (USD) (M) 12,347PerformanceYTD1M6M12MAbsolute (%)(3.9)(31.7)3.8(34.8)SPX (%)9.24.39.728.8Relative (%)(13.1)(36.0)(5.9)(63.6)Source: Bloomberg, Bernstein estimates and analysis.Price Performance, 1YR$35$30$25$20$1505/2508/2511/2502/2605/2660006500700075008000SMMTSPXSee the Disclosure Appendix of this report for required disclosures, analyst certifications and otherimportant information. Alternatively, visit our Global Research Disclosure Website.www.bernsteinresearch.comFirst Published: 26 May 2026 00:00 UTC Completion Date: 22 May 2026 16:47 UTC Jeffrey Walch +1 917 344 8613 jeffrey.walch@bernsteinsg.com26 May 2026DETAILSKey messages:1. We expect HARMONi6’s ASCO presentation to show non-statistically significant overall survival at interim analysis: OS trendHR >0.722 is likely in the absence of a pre-conference press release.2. HARMONi's pending FDA decision is a false catalyst: Toss-up for approval in a competitive patient po...